Leadership Overview
TriRx Pharmaceutical Services has 4 executives leading key functions including strategy, operations, finance, and human resources.
Driven by a commitment to pharmaceutical excellence, TriRx Pharmaceutical Services delivers advanced manufacturing and development solutions to global clients while maintaining rigorous quality standards across all sterile and non-sterile production facilities.
Driven by a commitment to pharmaceutical excellence, TriRx Pharmaceutical Services delivers advanced manufacturing and development solutions to global clients while maintaining rigorous quality standards across all sterile and non-sterile production facilities.
Leadership Roles at TriRx Pharmaceutical Services
Timothy Tyson - Chairman & Chief Executive Officer
Timothy Tyson, the Chairman & Chief Executive Officer at TriRx Pharmaceutical Services, directs the overarching strategic vision for the organization. By aligning corporate objectives with the complex demands of the contract development and manufacturing sector, Tyson ensures the company maintains a competitive edge in both sterile and non-sterile product markets. This leadership role involves constant engagement with the Board to refine long-term growth trajectories and expand the global footprint of the firm. Overseeing the integration of advanced analytics and development capabilities, the Chairman & Chief Executive Officer drives operational excellence across all international sites. Timothy Tyson fosters a culture of innovation that supports pharmaceutical partners in bringing critical products to market efficiently. Through precise resource allocation and market analysis, the executive secures the financial and operational health of the enterprise while navigating the evolving regulatory landscape of the global pharmaceutical industry.
Keith Lyon - Executive Vice President & Chief Financial Officer
Keith Lyon, the Executive Vice President & Chief Financial Officer at TriRx Pharmaceutical Services, governs the financial architecture and fiscal health of the organization. By managing capital investments, budgeting, and financial reporting, Lyon ensures the company possesses the necessary resources to support expansion and technological upgrades in manufacturing facilities. The Executive Vice President & Chief Financial Officer analyzes market trends to inform strategic decision-making and risk management protocols. Keith Lyon collaborates with the executive team to evaluate the profitability of new service offerings and potential acquisitions within the pharmaceutical sector. This leadership position involves maintaining transparent communication with stakeholders regarding the financial performance and growth potential of the firm. By optimizing cash flow and cost structures, the executive provides the stability required for long-term success. Lyon drives fiscal discipline across all departments, ensuring that every investment aligns with the core mission of delivering superior contract development and manufacturing services.
Jim Scandura - Co-Founder & Director & Executive Vice President & Chief Operating Officer
Jim Scandura, the Co-Founder & Director & Executive Vice President & Chief Operating Officer at TriRx Pharmaceutical Services, manages the daily execution of manufacturing and packaging operations. Focusing on the technical infrastructure within the Huntsville and Segré facilities, Scandura optimizes production workflows to meet the high-volume requirements of animal health injectables and human pharmaceutical products. The Co-Founder & Director & Executive Vice President & Chief Operating Officer coordinates cross-functional teams to ensure seamless transitions from development to commercial-scale manufacturing. By implementing lean manufacturing principles, Jim Scandura enhances operational efficiency and reduces time-to-market for diverse client portfolios. This role requires constant oversight of supply chain logistics and facility maintenance to uphold stringent quality standards. Through rigorous process management, the executive ensures that all production lines operate at peak capacity, directly supporting the company's mission to provide reliable, high-quality manufacturing solutions to the global pharmaceutical market.
Richard Mark - Chief Human Resources Officer
Richard Mark, the Chief Human Resources Officer at TriRx Pharmaceutical Services, architects the talent acquisition and organizational development strategies necessary to sustain a high-performance workforce. By cultivating a culture of technical expertise and operational safety, Mark ensures the company attracts and retains top-tier professionals capable of managing complex sterile and non-sterile manufacturing processes. The Chief Human Resources Officer designs comprehensive training programs that align with the evolving needs of the pharmaceutical industry and the specific requirements of the Huntsville and Segré facilities. Richard Mark oversees performance management systems and employee engagement initiatives to drive productivity and organizational alignment. This role involves partnering with other C-suite leaders to ensure that human capital strategies support the broader business objectives of the firm. Through effective workforce planning and leadership development, the executive builds a resilient team capable of meeting the rigorous demands of global pharmaceutical clients while maintaining a focus on professional growth and operational excellence.
Explore Leadership Teams in Manufacturing
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience, serving patients across international markets through research-driven innovation.
Company Leadership NM
VS
Cipla Limited is a global pharmaceutical company based in Mumbai, India, with operations in India, the United States, South Africa, and other international markets. Through its Pharmaceuticals and New Ventures segments, the company develops, manufactures, markets, and distributes a broad range of generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and finished formulations. Its products address multiple therapeutic areas, including cardiovascular disease, pulmonary and kidney conditions, neurological and psychiatric disorders, HIV/AIDS, respiratory and asthma care, oncology, diabetes and metabolic disorders, infectious diseases, critical care, women’s health, ophthalmology, and child health. In addition to its core pharmaceutical portfolio, Cipla is active in consumer healthcare, biosimilars, and specialty medicine businesses. Founded in 1935, Cipla has grown into a major global healthcare player.
Company Leadership MF
PJ
KI
Founded in 1947 and headquartered in Mumbai, Indoco Remedies Limited is a fully integrated, research-oriented pharma company. Indoco specializes in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
Company Leadership PA
AR
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CC
BS
SR
Frequently Asked Questions Regarding TriRx Pharmaceutical Services Top Executives and Leadership Team
